伴有抑郁症状急性冠脉综合征早期应用氟哌噻吨美利曲辛疗效观察

摘要

目的 探讨药物干预对伴有抑郁症状的急性冠脉综合征( ACS)患者的临床疗效.方法将入选的94例合并抑郁ACS患者随机分为干预组(n=48)和对照组(n=46).干预组在冠心病常规治疗上给予氟哌噻吨美利曲辛.两组治疗前后HAMD评分、临床症状和超敏C反应蛋白(hs-CRP)进行比较.结果 干预组治疗后HAMD评分明显低于对照组[( 13±7)vs(26±7),P＜0.05].干预组治疗后临床症状改善率明显优于对照组(P＜0.05).干预组治疗在观察中期和结束时hs-CRP水平下降优于对照组[6周时(12.7±4.7) vs (21.3±5.3) mg/L; 12周时(8.2±2.2)vs(17.5±4.4) mg/L,P＜ 0.05].结论对合并抑郁的ACS患者早期使用氟哌噻吨美利曲辛不仅可以改善抑郁症状,并有助于提早改善冠心病临床症状,降低hs-CRP水平,对ACS患者早期康复及近期预后有重要意义.%Objective To investigate the effect of drug intervention on acute coronary syndrome(ACS) patients complicated with depression. Methods Ninety-four ACS patients with depression were randomly divided into intervention group(n=48) and control group(n=46). The patients in intervention group were given anti-psychotropic drug, flupentixol and melitracen tablets, besides routine therapy, while the patients in control group were give routine therapy only. The Hamilton Depression Rating Scale (HAMD), clinical symptoms and levels of high sensititvity C-reactive protein (hs-CRP) were compared between the two groups before and after treatment. Results After treatment, the HAMD scores in intervention group were significantly lower than those in control group [(13 ± 7) vs (26 ±7), P < 0.05]. Clinical symptoms improvement was more significant in intervention group than in control group after treatment(P < 0.05). Levels of hs-CRP were decreased more significantly in intervention group than in control group during the whole therapy course [6 weeks: (12.7 ±4.7) vs (21.3 ±5.3) mg/L; 12 weeks: (8.2 ±2.2) vs (17.5 ±4.4) mg/L, P < 0.05]. Conclusion For ACS patients with depression, early administration of flupentixol and melitracen tablets can improve clinical symptoms not only in respect of depression but also in respect of coronary artery disease, and reduce levels of hs-CRP. Flupentixol and melitracen tablets play significant roles in rapid recovery and short-term prognosis of ACS patients with depression.